|5.84|| -0.01 / -0.17%|
Regulus Therapeutics, Inc. discovers and develops pharmaceutical products. It is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a broad range of diseases. The company intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases. It is developing RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy, and RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection. Regulus Therapeutics was founded in September 2007 and is headquartered in San Diego, CA.
|Paul C. Grint||President, Chief Executive Officer & Director|
|Joseph P. Hagan||Chief Operating, Financial & Accounting Officer|
|Michael Huang||Vice President-Clinical Development|
|Daniel R. Chevallard||Vice President-Finance & Accounting|
|Amy Conrad||Director-Investor Relations & Communications|